Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 9, 2024The FASEB JournalOpen Access

1‐Deoxynojirimycin attenuates pathological markers of Alzheimer's disease in the in vitro model of neuronal insulin resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

IPIsabella Supardi ParidaSTSoo TakasuJIJunya Ito

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Parida et al. (2024) studied this question.

synapsesocial.com/papers/68e60e42b6db6435875a10f2https://doi.org/10.1096/fj.202302600r
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Metabolic Modulation of Type 2 Diabetes Mellitus by 1-Deoxynojirimycin: A Multifaceted Approach2026 · 1 citations
  2. 2D-chiro-inositol modulates brain insulin-related signaling and reduces amyloid burden, neuroinflammation and cognitive decline in preclinical models of Alzheimer's disease2026
  3. 3Insulin resistance as a driver of neuroinflammation and oxidative stress in Alzheimer's disease: Mechanistic links and therapeutic approaches2026
  4. 4219-OR: Loss of Insulin Signaling in Microglia Impairs Cellular Uptake of Aß and Neuroinflammatory Response Exacerbating Alzheimer-Like Neuropathology2024
  5. 5Critical Review of 1-Deoxynojirimycin (DNJ) 
in Mulberry in Curing Diabetes Mellitus2025